Title: A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
Principal Investigator: Jennifer Veneris, MD,PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Description: Researchers are conducting a single-arm phase 2 trial to investigate if the combination of mirvetuximab soravtansine and pembrolizumab could improve responses in participants with endometrial cancer.
Continue Reading
Trial participants must have advanced or recurrent serous endometrial cancer with tumors that are deemed microsatellite stable (MSS) and FRα positive. They must have had 1 prior therapy, but no more than 3 prior lines of chemotherapy, for endometrial carcinoma.
Patients who have had chemotherapy within 5 half-lives or 4 weeks (whichever is shorter) or radiotherapy within 2 weeks prior to the study enrollment date are excluded from the trial, as well as any patients who are receiving any other investigational agents or have received checkpoint inhibitors targeting the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) pathway.
To read the complete list of inclusion and exclusion criteria please refer to the reference.
Status: This trial is ongoing and recruiting patients as of February 11, 2019
This study is sponsored by Dana-Farber Cancer Institute, ImmunoGen, Inc., and Merck Sharp & Dohme Corp.
Reference
Clinicaltrials.gov. A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC). NCT03835819. https://clinicaltrials.gov/ct2/show/NCT03835819. Accessed October 26, 2020.
